Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial

INTRODUCTION: Universal coverage of vaccines alone cannot be relied upon to protect at-risk populations in lower- and middle-income countries against the impact of the coronavirus disease 2019 (COVID-19) pandemic and newer variants. Live vaccines, including Bacillus Calmette–Guérin (BCG), are being...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Sanjeev, Ajayababu, Anuj, Thukral, Himanshu, Gupta, Sushil, Guha, Subhasish Kamal, Basu, Ayan, Gupta, Gaurav, Thakur, Prashant, Lingaiah, Raghavendra, Das, Bimal Kumar, Singh, Urvashi B., Singh, Ravinder, Narang, Rajiv, Bhowmik, Dipankar, Wig, Naveet, Modak, Dolan Champa, Bandyopadhyay, Bhaswati, Chakrabarty, Banya, Kapoor, Aditya, Tewari, Satyendra, Prasad, Narayan, Hashim, Zia, Nath, Alok, Kumari, Niraj, Goswami, Ravinder, Pandey, Shivam, Pandey, Ravindra Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568923/
https://www.ncbi.nlm.nih.gov/pubmed/36242739
http://dx.doi.org/10.1007/s40121-022-00703-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568923/
https://www.ncbi.nlm.nih.gov/pubmed/36242739
http://dx.doi.org/10.1007/s40121-022-00703-y

Ejemplares similares